The UK government has revealed plans to give patients more of a say in how clinical trials are designed and managed. It is also planning to update current its Good Clinical Practice principles to make sure they are “flexible and can be applied to a broad range of clinical trials.”
New rules are also being proposed for investigational medicinal products (IMPs), including risk-proportionate requirements for authorized IMPs used in trials,...